12 November 2021
EMA/PDCO/601596/2021
Human Medicines Division

Paediatric Committee (PDCO)

Minutes for the meeting on 12-15 October 2021

Chair: Koenraad Norga – Vice-Chair: Sabine Scherer

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 17 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

Due to restricted involvement, the Chair Koenraad Norga deputised chairing the meeting to the Vice-Chair Sabine Scherer for the agenda topic(s) 2.1.23, 2.1.24, 2.3.21, 3.1.32 and 3.2.6.

1.2. Adoption of agenda

The agenda for 12-15 October meeting was adopted.

1.3. Adoption of the minutes

The minutes for 7-10 September 2021 meeting were adopted and will be published on the EMA website.

2. Opinions

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain (BI 456906) - EMEA-002942-PIP01-20

Boehringer Ingelheim International GmbH; Treatment of non-alcoholic steatohepatitis

Day 120 opinion

Gastroenterology-Hepatology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children from 8 years to less than 18 years, in the condition of treatment of non-alcoholic steatohepatitis was adopted. The PDCO agreed on a waiver in a subset of children from birth to less than 8 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments. The PDCO granted a deferral for the completion of this PIP.

2.1.2. Marzeptacog alfa (activated) - Orphan - EMEA-002270-PIP03-20

Catalyst Biosciences, Inc.; Treatment of haemophilia A

Day 120 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for all age paediatric age groups in the condition of treatment of haemophilia A and a deferral was adopted.

2.1.3. Marzeptacog alfa (activated) - Orphan - EMEA-002270-PIP04-20

Catalyst Biosciences, Inc.; Treatment of haemophilia B

Day 120 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for all age paediatric age groups in the condition of treatment of haemophilia B and a deferral was adopted.

2.1.4. Ravulizumab - EMEA-001943-PIP04-20

Alexion Europe SAS; Treatment of neuromyelitis optica spectrum disorders

Day 120 opinion

Neurology

Summary of Committee discussion:

The PDCO adopted a positive opinion on a PIP, including a waiver in children from birth to less than 2 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible and a deferral for the clinical and extrapolation studies.

2.1.5. Satralizumab - Orphan - EMEA-001625-PIP02-21

Roche Registration GmbH; Treatment of myasthenia gravis

Day 120 opinion

Neurology

Summary of Committee discussion:

The PDCO adopted a positive opinion on a PIP, including a waiver in children from birth to less than 2 years of age on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need and a deferral for the paediatric clinical study and for the extrapolation study.

2.1.6. Lutetium (^{177}Lu) oxodotreotide - Orphan - EMEA-002950-PIP01-20

Advanced Accelerator Applications; Treatment of gastroenteropancreatic neuroendocrine tumours

Day 120 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at day 120 during the October 2021 plenary meeting, an application for a PIP for lutetium (^{177}Lu) oxodotreotide for the treatment of gastroenteropancreatic neuroendocrine tumours.
The PDCO confirmed all the conclusions reached at Day 90.
The PDCO adopted a positive opinion on a paediatric investigation plan for the treatment of gastroenteropancreatic neuroendocrine tumours for adolescents from 12 years to less than 18 years of age, with a waiver for children from birth to less than 12 years of age on the grounds that the disease for which the specific medicinal product is intended does not occur in the specified paediatric subset.

2.1.7. Magrolimab - Orphan - EMEA-002819-PIP01-20

Gilead Sciences International Ltd; Treatment of acute myeloid leukaemia / Treatment of myelodysplastic syndromes (including juvenile myelomonocytic leukaemia)

Day 120 opinion

Oncology

Summary of Committee discussion:

In the written response the applicant addressed the remaining issues raised by the Committee.
Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for the paediatric population from 28 days to less than 18 years of age in the conditions of treatment of acute myeloid leukaemia and treatment of myelodysplastic syndromes (including juvenile myelomonocytic leukaemia) was adopted. The PDCO agreed on a waiver in the age subset from birth to less than 28 days of age based on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s). The PDCO granted a deferral for the completion of this PIP.

2.1.8. 2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA - Orphan - EMEA-002981-PIP01-21

Antisense Therapeutics Limited; Treatment of Duchenne muscular dystrophy

Day 120 opinion

Other

Summary of Committee discussion:

In October 2021 the PDCO was informed that all remaining issues were resolved. Therefore, the PDCO adopted a positive opinion on a PIP for 2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA (ATL1102) for the treatment of Duchenne muscular dystrophy with a deferral and a waiver for the paediatric population from birth to less than 2 years. The PIP consists in 4 clinical studies and a modelling and simulation study.

2.1.9. Evenamide - EMEA-002519-PIP03-21

Newron Pharmaceuticals SpA; Treatment of schizophrenia

Day 120 opinion

Psychiatry

Summary of Committee discussion:

The PDCO discussed in October 2021 the responses of the applicant to the Day 90 discussion. The PDCO agreed a PIP for evenamide for the treatment of schizophrenia with a deferral and a waiver for the paediatric population from birth to less than 13 years of age on the grounds that the condition does not occur in the specified paediatric subset.

2.1.10. *Neisseria meningitidis* serogroup B Protein-based active substance / Recombinant *Neisseria meningitidis* serogroup B protein 1 / Recombinant *Neisseria meningitidis* serogroup B protein 3 / Recombinant *Neisseria meningitidis* serogroup B protein 2 - EMEA-002954-PIP02-21

Sanofi Pasteur; Prevention of meningococcal disease

Day 120 opinion

Vaccines

Summary of Committee discussion:

The PDCO re-discussed at Day 120, during the October 2021 plenary meeting, an application for a PIP for Recombinant *Neisseria meningitidis* serogroup B protein 1 / Recombinant *Neisseria meningitidis* serogroup B protein 2 / Recombinant *Neisseria meningitidis* serogroup B protein 3 / *Neisseria meningitidis* serogroup B Protein-based active substance for the prevention of meningococcal disease.
The PDCO confirmed all conclusions reached at Day 90 and adopted a positive opinion on a paediatric investigation plan for the prevention of meningococcal disease for children from 6 weeks to less than 18 years of age with a deferral and with a waiver for children from birth to less than 6 weeks of age on the grounds that the specific medicinal product is likely to be ineffective in the specified paediatric subset.

2.1.11. Amlodipine (besilate) / ramipril - EMEA-003070-PIP01-21

1A Pharma GmbH; Treatment of hypertension

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for ramipril / amlodipine (besilate) for all subsets of the paediatric population (birth to less than 18 years of age) in the condition "treatment of hypertension".

2.1.12. Furosemide / eplerenone - EMEA-003065-PIP01-21

Przedsiębiorstwo Farmaceutyczne LEK-AM Sp. z o.o.; Treatment of heart failure

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the assessment of this application and discussions at the Paediatric Committee the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for the proposed medicine for all subsets of the paediatric population (from birth to less than 18 years of age) for the condition treatment of heart failure on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.13. Verdiperstat - Orphan - EMEA-002708-PIP02-21

Biohaven Pharmaceutical Ireland DAC; Treatment of amyotrophic lateral sclerosis

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for verdiperstat for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of amyotrophic lateral sclerosis, on the grounds of lack of significant therapeutic benefit (as clinical trials are not be feasible) in all paediatric age subsets.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. The PDCO identified amyotrophic lateral sclerosis as an unmet need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.14. Adagrasib - EMEA-003068-PIP01-21

Mirati Therapeutics, Inc.; Treatment of all solid and haematological malignancies

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for adagrasib for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of all solid and haematological malignancies based on the ground that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.15. Adagrasib - EMEA-003068-PIP02-21

Treatment of colorectal cancer

Day 60 opinion

Oncology

Note: Withdrawal request received on 14 October 2021

2.1.16. Adavosertib - EMEA-003069-PIP01-21

AstraZeneca AB; Treatment of pancreatic cancer / Treatment of malignant endometrial neoplasms

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 60 during the October 2021 plenary meeting, an application for a product-specific waiver for adavosertib for the treatment of malignant endometrial neoplasms and treatment of malignant pancreatic neoplasms.
The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion on a product specific waiver for adavosertib for all subsets of the paediatric population (from birth to less than 18 years of age) in the conditions of treatment of malignant endometrial neoplasms and treatment of pancreatic cancer on the grounds that the disease does not occur in the paediatric population.

2.1.17. Ofranergene obadenovec - Orphan - EMEA-003062-PIP01-21

Vascular Biogenics Ltd. (VBL Therapeutics); Treatment of fallopian tube cancer / Treatment of peritoneal cancer / Treatment of ovarian cancer

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 60 during the October 2021 plenary meeting, an application for a product-specific waiver for ofranergene obadenovec, an anti-angiogenic gene therapy product.
The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion on a product specific waiver for ofranergene obadenovec for all subsets of the paediatric population (from birth to less than 18 years of age) in the conditions of treatment of ovarian cancer, treatment of fallopian tube cancer and treatment of peritoneal cancer on the grounds that the disease does not occur in the paediatric population.

2.1.18. Pamrevlumab - EMEA-002979-PIP03-21

FibroGen, Inc; Treatment of pancreatic cancer

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 60, during the October 2021 plenary meeting, an application for a product specific waiver for pamrevlumab, a monoclonal antibody directed against connective tissue growth factor (CTGF), for the treatment of pancreatic cancer on the basis that this condition does not occur in the paediatric population.
The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion on a

product specific waiver for pamrevlumab for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of treatment of pancreatic cancer on the grounds that the disease does not occur in the paediatric population.

2.1.19. Vibostolimab / pembrolizumab - EMEA-003063-PIP01-21

Merck, Sharp & Dohme (Europe) Inc; Treatment of all conditions included in the category of malignant neoplasms (except nervous system neoplasms, haematopoietic and lymphoid tissue neoplasms and melanoma) / Treatment of malignant neoplasms of the central nervous system

Day 60 opinion

Oncology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the assessment of this application and discussions at the Paediatric Committee the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for the proposed medicine for all subsets of the paediatric population (from birth to less than 18 years of age) for the conditions 'treatment of all conditions included in the category of malignant neoplasms (except nervous system neoplasms, haematopoietic and lymphoid tissue neoplasms and melanoma)' and 'treatment of malignant neoplasms of the central nervous system' on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2.1.20. Otenaproxesul - EMEA-003061-PIP01-21

Antibe Therapeutics Inc.; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)

Day 60 opinion

Pain

Summary of Committee discussion:

Based on the assessment of this application, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for otenaproxesul for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis) on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.1.21. Benralizumab - EMEA-001214-PIP08-21

AstraZeneca AB; Treatment of non-cystic fibrosis bronchiectasis with an eosinophilic phenotype

Day 60 opinion

Pneumology - Allergology

Summary of Committee discussion:

The PDCO confirmed the outcome of Day 30 discussion and based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant´s request for a waiver.
The PDCO recommends granting a waiver for benralizumab for all subsets of the paediatric population (from birth to less than 18 years of age) for the condition of treatment of non-cystic fibrosis bronchiectasis with an eosinophilic phenotype on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2.1.22. Bis-(3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-beta-D-galactopyranosyl) sulfane - Orphan - EMEA-003060-PIP01-21

Galecto Biotech AB; Idiopathic pulmonary fibrosis

Day 60 opinion

Pneumology - Allergology

Note: Withdrawal request received on 14 October 2021

2.1.23. Depemokimab - EMEA-003051-PIP02-21

Eosinophilic granulomatosis with polyangiitis (EGPA)

Day 60 opinion

Pneumology – Allergology

Note: Withdrawal request received on 28 September 2021

2.1.24. Depemokimab - EMEA-003051-PIP03-21

Treatment of hypereosinophilic syndrome (HES)

Day 60 opinion

Pneumology – Allergology

Note: Withdrawal request received on 28 September 2021

2.1.25. Human alpha1-proteinase inhibitor - EMEA-001525-PIP02-21

Kamada Ireland Limited; Treatment of emphysema secondary to congenital deficiency of alpha-1 antitrypsin

Day 60 opinion

Pneumology - Allergology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric

Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for human alpha1-proteinase inhibitor for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of emphysema secondary to congenital deficiency of alpha-1 antitrypsin, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset.
The PDCO recommended to grant the waiver for all pharmaceutical forms and all routes of administration to which the applicant agreed.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need.

2.1.26. Pamrevlumab - EMEA-002979-PIP02-21

Idiopathic pulmonary fibrosis

Day 60 opinion

Pneumology - Allergology

Note: Withdrawal request received on 15 October 2021

2.1.27. Influenza virus surface antigen (haemagglutinin and neuraminidase) of strain A/H5N1 - EMEA-002869-PIP02-21

Influenza due to identified zoonotic or pandemic influenza virus

Day 60 opinion

Vaccines

Note: Withdrawal request received on 28 September 2021

2.1.28. Inactivated poliovirus: type 3 (Saukett strain) / Inactivated poliovirus: type 2 (MEF-1 strain) / Inactivated poliovirus: type 1 (Mahoney strain) / *Bordetella pertussis* antigen: Pertactin / *Bordetella pertussis* antigen: Filamentous Haemagglutinin / *Bordetella pertussis* antigen: Pertussis toxoid / Tetanus toxoid / Diphtheria toxoid - EMEA-003066-PIP01-21

Vakzine Projekt Management GmbH; Prevention of infectious diseases caused by *Corynebacterium diphtheriae*, *Clostridium tetani*, *Bordetella pertussis*, Poliovirus types 1, 2 and 3

Day 60 opinion

Vaccines / Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for *Bordetella pertussis* antigen: Pertactin / Inactivated poliovirus: type 3 (Saukett strain) / Diphtheria toxoid / Tetanus toxoid / Inactivated poliovirus: type 1 (Mahoney strain) / Inactivated poliovirus: type 2 (MEF-1 strain) /

Bordetella pertussis antigen: Pertussis toxoid / Bordetella pertussis antigen: Filamentous Haemagglutinin for all subsets of the paediatric population (0 to 18 years of age) in the condition of prevention of infectious diseases caused by *Corynebacterium diphtheriae*, *Clostridium tetani*, *Bordetella pertussis*, Poliovirus types 1, 2 and 3.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need.

2.1.29. RSV F protein - EMEA-003094-PIP01-21

Prevention of lower respiratory tract disease caused by respiratory syncytial virus

Day 60 opinion

Vaccines / Infectious Diseases

Note: Withdrawal request received on 14 October 2021

2.1.30. Human normal immunoglobulin - EMEA-003076-PIP01-21

Octapharma Pharmazeutika Produktionsges.m.b.H; Treatment of primary immunodeficiency

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the assessment of this application and discussions at the Paediatric Committee the PDCO disagrees with the applicant's proposal for the paediatric investigation plan for human normal immunoglobulin in children from birth to less than 18 years of age. The PDCO therefore recommends granting a waiver for human normal immunoglobulin for all subsets of the paediatric population from birth to less than 18 years of age in the condition of treatment of primary immunodeficiency of its own motion based on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.2. Opinions on Compliance Check

The following compliance checks have been identified for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

2.2.1. Dolutegravir (DTG) - EMEA-C-000409-PIP01-08-M06

ViiV Healthcare UK Limited; Treatment of human immunodeficiency virus (HIV-1) infection

Day 30 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO took note in October 2021 of outcomes of preceding partial compliance check procedures:

- EMEA-C1-000409-PIP01-08-M02

The PDCO adopted on an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0267/2021) of 9 July 2021.

2.2.2. Aflibercept - EMEA-C-000236-PIP05-18

Bayer AG; Retinopathy of prematurity (ROP)

Day 30 opinion

Ophthalmology

Summary of Committee discussion:

The PDCO adopted on 15 October 2021 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0115/2019) of 4 April 2019.

2.2.3. Fosdenopterin - EMEA-C-001491-PIP01-13-M01

Comharsa Life Sciences Limited; Treatment of molybdenum cofactor deficiency type A

Day 30 opinion

Other

Summary of Committee discussion:

The PDCO adopted on 15 October 2021 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0048/2021) of 13 October 2020.

2.2.4. Oseltamivir (phosphate) - EMEA-C-000365-PIP01-08-M12

Roche Registration GmbH; Treatment and prevention of influenza

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:

- EMEA-C3-000365-PIP01-08-M06

The PDCO adopted on 15 October 2021 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0241/2021) of 23 March 2021.

2.2.5. Ceftobiprole medocaril (sodium) - EMEA-C1-000205-PIP02-11-M04

Basilea Pharmaceutica International Ltd; Treatment of pneumonia

Day 60 letter

Infectious Diseases

Summary of Committee discussion:

The PDCO confirmed that the study 1, study 5 and study 6 are compliant with the latest Agency's Decision (P/0311/2020) of 14 August 2020.
The PDCO finalised this partially completed compliance procedure on 15 October 2021.

2.2.6. Ruxolitinib phosphate - EMEA-C1-002618-PIP02-20

Incyte Biosciences Distribution B.V.; Treatment of vitiligo

Day 30 letter

Dermatology

Summary of Committee discussion:

The PDCO discussed the completed study(ies) and considered that these are compliant with the latest Agency's Decision (P/0145/2021) of 16 April 2021.
The PDCO finalised this partially completed compliance procedure on 15 October 2021.

2.2.7. Zanubrutinib - EMEA-C1-002354-PIP02-18

BeiGene Ireland Ltd; Treatment of mature B cell neoplasms (excluding lymphoplasmacytic lymphoma)

Day 60 letter

Oncology

Summary of Committee discussion:

The PDCO discussed the completed study 2 and considered that, taking into account the clarification provided by the applicant after D30, it is compliant with the latest Agency's Decision (P/0398/2019) of 4 December 2019.
The PDCO finalised this partially completed compliance procedure on 15 October 2021.

2.2.8. Cipaglucosidase alfa - EMEA-C3-002447-PIP01-18-M01

Amicus Therapeutics Europe Limited; Treatment of glycogen storage disease Type II (Pompe's disease)

Day 30 letter

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

The PDCO considers that study 4 initiation is compliant with the latest PIP.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Bilastine - EMEA-000347-PIP02-16-M03

Faes Farma S.A.; Treatment of allergic conjunctivitis

Day 60 opinion

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0466/2020 of 1 December 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.2. 3,4-Dimethoxy-N-methylbenzohydroxamic acid / Deferoxamine mesylate / Alfa-ketoglutaric acid / Arginine / Alanine / Glycine / Aspartic acid / Tryptophan / N-acetyl-histidine (monohydrate) / Histidine / Calcium chloride (dihydrate) / Magnesium chloride (hexahydrate) / Potassium chloride / Sodium chloride - EMEA-002735-PIP03-20-M01

Dr. Franz Köhler Chemie GmbH; Heart transplantation

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0190/2021 of 10 May 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.3. Azilsartan medoxomil - EMEA-000237-PIP01-08-M10

Takeda Development Centre Europe Ltd; Treatment of hypertension

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

The PDCO re-discussed at Day 60, during the October 2021 plenary meeting, a modification for azilsartan medoxomil for the treatment of hypertension.
Based on the review of the documentation submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that some of the proposed changes could be accepted.
Therefore, the PDCO adopted a positive opinion on the modification of the agreed PIP as set

in the Agency's latest decision (P/0158/2021 of 14 April 2021).

2.3.4. Macitentan - Orphan - EMEA-001032-PIP01-10-M04

Janssen-Cilag International NV; Treatment of idiopathic pulmonary fibrosis / Treatment of pulmonary arterial hypertension / Treatment of systemic sclerosis

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0049/2016 of 18 March 2016).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.5. Vericiguat - EMEA-001636-PIP01-14-M02

Bayer AG; Treatment of left ventricular failure

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, including the new information submitted after Day 30, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0070/2017 of 17 March 2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.6. Glycopyrronium bromide - EMEA-002383-PIP01-18-M01

Dr. August Wolff GmbH & Co. KG - Arzneimittel; Treatment of hyperhidrosis

Day 60 opinion

Dermatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that some proposed changes could be accepted. The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision P/0420/2020. The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.7. Cotadutide - EMEA-002287-PIP01-17-M03

AstraZeneca AB; Treatment of type 2 diabetes mellitus

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0270/2021 of 9 July 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.8. Evinacumab - EMEA-002298-PIP01-17-M03

Regeneron Ireland DAC; Treatment of elevated cholesterol

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0069/2021 of 17 March 2021).

2.3.9. Sodium zirconium cyclosilicate - EMEA-001539-PIP01-13-M05

AstraZeneca AB; Treatment of hyperkalaemia

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0069/2020 of 18 March 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.10. Naloxegol - EMEA-001146-PIP01-11-M07

Kyowa Kirin Pharmaceutical Development Limited; Treatment of opioid-induced constipation

Day 60 opinion

Gastroenterology-Hepatology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0513/2020 of 22 December 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.11. Marstacimab - Orphan - EMEA-002285-PIP02-19-M01

Pfizer Europe MAA EEIG; Treatment of congenital haemophilia A / Treatment of congenital haemophilia B

Day 60 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

The PDCO reviewed the conclusions reached at Day 30.
All the other modifications were found acceptable and the PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0292/2020 of 12 August 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.12. Vonicog alfa - EMEA-001164-PIP01-11-M05

Baxalta Innovations GmbH; Treatment of von Willebrand disease

Day 60 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision P/0463/2020 issued on 4 December 2020.
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.13. Upadacitinib - EMEA-001741-PIP01-14-M05

AbbVie Ltd; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that some proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0167/2021 of 14 April 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.14. Baloxavir marboxil - EMEA-002440-PIP01-18-M02

Roche Registration GmbH; Treatment of influenza / Prevention of influenza

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

The applicant provided responses to the issue raised during D30 discussion. The proposed approach was considered acceptable.

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0029/2021 of 29 January 2021).

The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.15. Ceftobiprole medocaril sodium - EMEA-000205-PIP02-11-M05

Basilea Pharmaceutica International Ltd.; Treatment of pneumonia

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0311/2020 of 14 August 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.16. Dalbavancin - EMEA-000016-PIP01-07-M08

Allergan Pharmaceuticals International Limited; Treatment of acute bacterial skin and skin structure infections

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that some of the proposed changes could be accepted. The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0377/2019 of 4 December 2019).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.17. Isavuconazonium (sulfate) - Orphan - EMEA-001301-PIP02-12-M04

Basilea Pharmaceutica International Ltd.; Treatment of invasive aspergillosis / Treatment of mucormycosis

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO re-discussed at day 60 during the October 2021 plenary meeting, a modification for isavuconazonium (sulphate) for the treatment of invasive aspergillosis and the treatment of mucormycosis. The PDCO confirmed all the conclusions reached at Day 30. Based on the review of the documentation submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be acceptable.
The main changes relate to timelines.
Therefore, the PDCO adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0100/2019 of 22 March 2019).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.18. Oritavancin (diphosphate) - EMEA-001270-PIP01-12-M04

Menarini International Operations Luxembourg S.A.; Treatment of acute bacterial skin and skin structure infections

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO view expressed at Day 30 was re-discussed and endorsed, taking the applicant clarifications into account.
The PDCO adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0154/2021 of 16 April 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.19. Pretomanid - Orphan - EMEA-002115-PIP01-17-M04

Global Alliance for TB Drug Development; Treatment of multi-drug-resistant tuberculosis

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0340/2020 of 9 September 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.20. Rilpivirine (RPV) / dolutegravir (DTG) - EMEA-001750-PIP01-15-M05

ViiV Healthcare UK Limited; Treatment of human immunodeficiency virus (HIV-1) infection

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0209/2021 of 10/5/2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.21. Sotrovimab - EMEA-002899-PIP01-20-M01

GlaxoSmithKline Trading Services Ltd; Treatment of coronavirus disease 2019 (COVID-19)

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO discussed the responses received by the applicant.

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0240/2021 of 17 June 2021).

The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.22. Tecovirimat monohydrate - Orphan - EMEA-001205-PIP02-19-M01

SIGA Technologies, Inc.; Orthopoxvirus disease (smallpox, monkeypox, cowpox, and vaccinia complications)

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

The applicant provided responses to the issue raised during D30 discussion. The proposed approach was considered acceptable.

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0029/2021 of 29 January 2021).

The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.23. Tenofovir alafenamide / emtricitabine / bictegravir - EMEA-001766-PIP01-15-M04

Gilead Sciences International Ltd.; Treatment of human immunodeficiency virus (HIV-1) infection

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

The applicant provided additional feed-back in a consultation on a draft opinion. Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that some of proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0038/2021of 27/1/2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.24. Erenumab - EMEA-001664-PIP02-15-M05

Novartis Europharm Limited; Prevention of migraine headaches

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan and the information received after D30, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0233/2020 of 19 June 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.25. Perampanel - EMEA-000467-PIP01-08-M15

Eisai Europe Limited; Treatment of treatment-resistant epilepsies

Day 60 opinion

Neurology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that some proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0296/2020 of 12 August 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.26. Soticlestat - EMEA-002572-PIP02-19-M01

Takeda Pharma A/S; Treatment of Dravet syndrome / Treatment of Lennox-Gastaut syndrome

Day 60 opinion

Neurology

Summary of Committee discussion:

The PDCO reviewed and discussed the applicant's responses submitted after Day 30.
Considering the above and based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0317/2020 of 12 August 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.27. Cabozantinib - Orphan - EMEA-001143-PIP01-11-M04

Ipsen Pharma; Treatment of malignant solid tumours

Day 60 opinion

Oncology

Note: Withdrawal request received on 23 September 2021

2.3.28. Cyclophosphamide - EMEA-002644-PIP01-19-M01

Accord Healthcare S.L.U.; Treatment of all malignant neoplasms

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as

set in the Agency's latest decision (P/0191/2020 of 15 May 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.29. Larotrectinib - EMEA-001971-PIP02-16-M04

Bayer AG; Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)

Day 60 opinion

Oncology

Summary of Committee discussion:

In the written response the applicant addressed the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0076/2021). The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.30. Regorafenib - EMEA-001178-PIP01-11-M06

Bayer AG; Treatment of all conditions contained in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0141/2020 of 17 April 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.31. Ruxolitinib (phosphate) - EMEA-000901-PIP04-17-M02

Novartis Europharm Limited; Treatment of chronic Graft versus Host disease

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as

set in the Agency's latest decision (P/0384/2019 of 4 December 2019).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.32. Inotuzumab ozogamicin - Orphan - EMEA-001429-PIP01-13-M04

Pfizer Europe MA EEIG; Treatment of B cell acute lymphoblastic leukaemia

Day 60 opinion

Oncology / Haematology-Hemostaseology

Summary of Committee discussion:

The PDCO re-discussed at day 60 during the October 2021 plenary meeting, a modification for inotuzumab ozogamicin for the treatment of B cell acute lymphoblastic leukaemia.
The PDCO confirmed all the conclusions reached at Day 30. Based on the review of the documentation submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be acceptable. The main changes relate to timelines.
Therefore, the PDCO adopted a positive opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0062/2020 of 10 February 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.33. Vamorolone - Orphan - EMEA-001794-PIP02-16-M04

ReveraGen BioPharma Ltd; Treatment of Duchenne muscular dystrophy

Day 60 opinion

Other

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan including clarification after the first discussion in September 2021, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0080/2021 of 17/3/2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.34. Methoxflurane - EMEA-000334-PIP01-08-M10

Medical Developments UK Ltd; Treatment of acute pain

Day 60 opinion

Pain

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as

set in the Agency's latest decision (P/0178/2020 of 13 May 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.35. Molgramostim - Orphan - EMEA-002282-PIP01-17-M01

Savara Aps; Treatment of pulmonary alveolar proteinosis

Day 60 opinion

Pneumology - Allergology

Summary of Committee discussion:

The applicant provided satisfactory responses to the outstanding issues prior to Day 60.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0094/2019 of 22 March 2019).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.36. Tezepelumab - EMEA-001613-PIP01-14-M05

AstraZeneca AB; Treatment of asthma

Day 60 opinion

Pneumology – Allergology

Note: Withdrawal request received on 27 September 2021

2.3.37. Lumasiran - Orphan - EMEA-002079-PIP01-16-M02

Alnylam UK Limited; Treatment hyperoxaluria

Day 60 opinion

Uro-nephrology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan and clarifications received after D30, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0004/2020 of 6 January 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.38. Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2) / Influenza virus surface

antigens (haemagglutinin and neuraminidase) of strain A (H1N1) - EMEA-002068-PIP01-16-M04

Seqirus Netherlands; Prevention of influenza

Day 60 opinion

Vaccines

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision P/0084/2020. The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.39. Severe acute respiratory syndrome coronavirus 2 recombinant spike protein nanoparticle vaccine / matrix-M1 adjuvant (NVX-CoV2373) - EMEA-002941-PIP01-20-M01

Novavax CZ, a.s.; Prevention of coronavirus disease 2019 (COVID-19)

Day 60 opinion

Vaccines

Summary of Committee discussion:

The PDCO reviewed the responses by the applicant.

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0126/2021 of 15 March 2021).

The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.4. Opinions on Re-examinations

No item

2.5. Opinions on Review of Granted Waivers

No item

2.6. Finalisation and adoption of Opinions

No item

2.7. Partial Compliance Checks completed by EMA

The following partial compliance checks have been identified by the PME coordinator and PDCO rapporteur as not needing to be referred to the PDCO for discussion. The PDCO has been informed in writing.

2.7.1. Casirivimab - EMEA-C1-002964-PIP01-21

Regeneron Ireland DAC; Treatment of coronavirus disease 2019 (COVID-19)

Day 30 letter

Infectious Diseases

2.7.2. Imdevimab - EMEA-C1-002965-PIP01-21

Regeneron Ireland DAC; Prevention of coronavirus disease 2019 (COVID-19)

Day 30 letter

Infectious Diseases

2.7.3. Vadadustat - EMEA-C1-001944-PIP01-16-M02

Otsuka Pharmaceutical Development & Commercialisation Europe GmbH; Treatment of anaemia due to chronic disorders

Day 30 letter

Haematology-Hemostaseology

2.7.4. Recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2 (INN: narsoplimab) - EMEA-C1-002479-PIP01-18

Omeros Ireland Limited; Treatment in haematopoietic stem cell transplantation

Day 30 letter

Haematology-Hemostaseology

2.7.5. Abacavir (ABC) / lamivudine (3TC) / dolutegravir (DTG) - EMEA-C1-001219-PIP01-11-M05

ViiV Healthcare UK Limited; Treatment of human immunodeficiency virus (HIV-1) infection

Day 30 letter

Infectious Diseases

2.7.6. Formoterol fumarate dihydrate / glycopyrronium bromide / beclometasone dipropionate - EMEA-C2-001875-PIP02-18-M03

Chiesi Farmaceutici S.p.A.; Treatment of asthma

Day 30 letter

Pneumology - Allergology

2.7.7. Bardoxolone (methyl) - EMEA-C1-002488-PIP01-18

Reata Pharmaceuticals, Inc.; Treatment of Alport syndrome

Day 30 letter

Uro-nephrology

2.7.8. Daprodustat - EMEA-C1-001452-PIP01-13-M03

GlaxoSmithKline Trading Services Limited; Treatment of anaemia due to chronic disorders

Day 30 letter

Uro-nephrology

3. Discussion of applications

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Autologous CD34+ hematopoietic stem cells with a CRISPR-edited erythroid enhancer region of the BCL11A gene - Orphan - EMEA-002730-PIP03-21

Vertex Pharmaceuticals (Ireland) Limited; Treatment of sickle cell disease

Day 90 discussion

Haematology-Hemostaseology

3.1.2. Autologous CD34+ hematopoietic stem cells with a CRISPR-edited erythroid enhancer region of the BCL11A gene - Orphan - EMEA-002730-PIP04-21

Vertex Pharmaceuticals (Ireland) Limited; Treatment of beta-thalassemia intermedia and major

Day 90 discussion

Haematology-Hemostaseology

3.1.3. Leniolisib - Orphan - EMEA-002989-PIP01-21

Pharming Group N.V.; Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.4. Exebacase - EMEA-002947-PIP01-20

Treatment of *Staphylococcus aureus* blood stream infections (bacteraemia)

Day 90 discussion

Infectious Diseases

3.1.5. Tosatoxumab - Orphan - EMEA-002506-PIP03-21

Aridis Pharmaceuticals Inc; Treatment of *Staphylococcus aureus* pneumonia

Day 90 discussion

Infectious Diseases / Pneumology - Allergology

3.1.6. ION-1166998; a 2'-O-(2-methoxyethyl) modified antisense oligonucleotide targeting glial fibrillary acidic protein pre-mRNA - Orphan - EMEA-002822-PIP01-20

Ionis Pharmaceuticals; Alexander disease

Day 90 discussion

Neurology

3.1.7. Vatiquinone - Orphan - EMEA-001238-PIP03-21

PTC Therapeutics International; Treatment of Friedreich ataxia

Day 90 discussion

Neurology

3.1.8. EMEA-002635-PIP02-21

Treatment of advanced or metastatic malignancies harbouring ALK, ROS1, or NTRK1-3 alterations

Day 90 discussion

Oncology

3.1.9. Humanised KLB/FGFR1c monoclonal antibody - EMEA-003058-PIP01-21

Treatment of non-alcoholic steatohepatitis

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.10. Semaglutide / cagrilintide - EMEA-003059-PIP01-21

Treatment of obesity

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.11. Tezepelumab - EMEA-001613-PIP03-21

Eosinophilic esophagitis

Day 60 discussion

Gastroenterology-Hepatology

3.1.12. Clazakizumab - EMEA-001371-PIP02-21

Treatment of chronic active antibody mediated rejection (AMR) in kidney transplantation

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.13. Retinol palmitate - Orphan - EMEA-003073-PIP01-21

PROVEPHARM SAS; Prevention of bronchopulmonary dysplasia

Day 60 discussion

Neonatology - Paediatric Intensive Care

Note: Withdrawal request received on 1 October 2021

3.1.14. Cannabidiol - EMEA-001964-PIP03-21

Treatment of epilepsy with myoclonic atonic seizures

Day 60 discussion

Neurology

3.1.15. Censavudine - EMEA-003075-PIP01-21

Treatment of Aicardi-Goutières syndrome

Day 60 discussion

Neurology

3.1.16. Autologous tumour-infiltrating lymphocytes (TILs) isolated from a patient's cancer tissue and expanded ex vivo - EMEA-003072-PIP01-21

Treatment of advanced melanoma

Day 60 discussion

Oncology

3.1.17. Cedazuridine / decitabine - EMEA-003071-PIP01-21

Treatment of acute myeloid leukaemia

Day 60 discussion

Oncology / Haematology-Hemostaseology

3.1.18. Ilofotase alfa - EMEA-003067-PIP01-21

Treatment of sepsis-associated acute kidney injury

Day 60 discussion

Uro-nephrology

3.1.19. Lademirsen - Orphan - EMEA-003064-PIP01-21

Genzyme Europe B.V.; Treatment of Alport syndrome

Day 60 discussion

Uro-nephrology

3.1.20. Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H5N1 - EMEA-002869-PIP01-21

Influenza due to identified zoonotic or pandemic influenza virus

Day 60 discussion

Vaccines

3.1.21. Whole-cell heat-inactivated bacterial strains of *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus vulgaris* and *Enterococcus faecalis* - EMEA-003026-PIP02-21

Prevention of recurrent urinary tract infections

Day 60 discussion

Vaccines / Infectious Diseases / Uro-nephrology

3.1.22. Efgartigimod alfa - EMEA-002597-PIP07-21

Treatment of pemphigus

Day 30 discussion

Dermatology

3.1.23. Venglustat - Orphan - EMEA-001716-PIP06-21

Genzyme Europe B.V.; Treatment of Fabry disease

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.24. Resmetirom - EMEA-003087-PIP01-21

Treatment of non-alcoholic steatohepatitis

Day 30 discussion

Gastroenterology-Hepatology

3.1.25. Ritlecitinib - EMEA-002451-PIP02-21

Treatment of ulcerative colitis

Day 30 discussion

Gastroenterology-Hepatology

3.1.26. EMEA-003090-PIP01-21

Hereditary angioedema

Day 30 discussion

Haematology-Hemostaseology

3.1.27. Deucravacitinib - EMEA-002350-PIP04-21

Treatment of ulcerative colitis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.28. Secukinumab - EMEA-000380-PIP08-21

Giant cell arteritis / Treatment of giant cell arteritis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.29. Humanised IgG1K monoclonal antibody against interferon beta - Orphan - EMEA-003089-PIP01-21

Pfizer Europe MA EEIG; Treatment of dermatomyositis

Day 30 discussion

Immunology-Rheumatology-Transplantation / Dermatology

3.1.30. EMEA-003081-PIP01-21

Prevention of coronavirus disease 2019 / Treatment of coronavirus disease 2019

Day 30 discussion

Infectious Diseases

3.1.31. Bepirovirsen - EMEA-003082-PIP01-21

Treatment of chronic hepatitis B infection

Day 30 discussion

Infectious Diseases

3.1.32. Emvododstat - EMEA-003088-PIP01-21

Treatment of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.1.33. Lonafarnib - Orphan - EMEA-002516-PIP02-21

EigerBio Europe Limited; Treatment of hepatitis D virus infection

Day 30 discussion

Infectious Diseases

3.1.34. Molnupiravir - EMEA-002940-PIP02-21

Prevention of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.1.35. Plitidepsin - Orphan - EMEA-000095-PIP02-21

Pharma Mar, S.A.; Treatment of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.1.36. Phenylephrine / acetylcysteine / paracetamol - EMEA-003091-PIP01-21

Treatment of cold and flu-like symptoms with or without fever, mild or moderate pain, nasal

congestion and thick mucus secretion / Treatment of upper respiratory tract infections

Day 30 discussion

Infectious Diseases / Oto-rhino-laryngology

3.1.37. Ex vivo fused normal allogeneic human myoblast (MBN) with autologous human myoblast derived from Duchenne muscular dystrophy affected donor (MBDMD) - Orphan - EMEA-003078-PIP01-21

Dystrogen Therapeutics S.A.; Treatment of Duchenne muscular dystrophy

Day 30 discussion

Neurology

3.1.38. Troriluzole - EMEA-003084-PIP01-21

Treatment of hereditary spinocerebellar ataxia

Day 30 discussion

Neurology

3.1.39. CD30-directed genetically modified autologous T cells (CD30.CAR-T) - EMEA-003092-PIP01-21

Treatment of Hodgkin lymphoma

Day 30 discussion

Oncology

3.1.40. Derivative of pyrazolo [1,5-a] pyrimidine - EMEA-003086-PIP01-21

Treatment of solid tumours

Day 30 discussion

Oncology

3.1.41. Humanised IgG2k Fc-modified bispecific monoclonal antibody against CD3 and BCMA - Orphan - EMEA-003083-PIP01-21

Pfizer Europe MA EEIG; Treatment of multiple myeloma

Day 30 discussion

Oncology

3.1.42. Milademetan tosilate - Orphan - EMEA-003093-PIP01-21

Rain Therapeutics, Inc.; Treatment of liposarcomas

Day 30 discussion

Oncology

3.1.43. Benralizumab - EMEA-001214-PIP09-21

Treatment of eosinophilic granulomatosis with polyangiitis (EGPA)

Day 30 discussion

Pneumology - Allergology

3.1.44. Humanised IgG2 monoclonal antibody against APRIL - Orphan - EMEA-003085-PIP01-21

Otsuka Pharmaceutical Netherlands B.V.; Treatment of primary IgA nephropathy

Day 30 discussion

Uro-nephrology

3.1.45. SARS-CoV-2 virus, beta-propiolactone inactivated - EMEA-003077-PIP01-21

Prevention of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Vaccines

3.2. Discussions on Compliance Check

The following compliance checks have been identified for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

3.2.1. Landiolol hydrochloride - EMEA-C1-001150-PIP02-13-M04

Orpha-Devel Handels und Vertriebs GmbH; Treatment of supraventricular arrythmias

Day 30 discussion

Cardiovascular Diseases

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Nemolizumab - EMEA-001624-PIP01-14-M04

Galderma International S.A.S; Atopic dermatitis

Day 30 discussion

Dermatology

3.3.2. Alirocumab - EMEA-001169-PIP01-11-M05

sanofi-aventis recherche & développement; Treatment of elevated cholesterol

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.3. Drospirenone / estetrol monohydrate - EMEA-001332-PIP01-12-M05

Estetra SRL; Prevention of pregnancy

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.4. Romosozumab - EMEA-001075-PIP04-15-M04

UCB Pharma S.A.; Treatment of osteoporosis

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.5. Tirzepatide - EMEA-002360-PIP01-18-M01

Eli Lilly and Company Ltd; Type 2 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.6. Vedolizumab - EMEA-000645-PIP01-09-M08

Takeda Pharma A/S; Treatment of ulcerative colitis / Treatment of Crohn's disease

Day 30 discussion

Gastroenterology-Hepatology

3.3.7. Crizanlizumab - Orphan - EMEA-002141-PIP01-17-M03

Novartis Europharm Limited; Treatment of sickle cell disease

Day 30 discussion

Haematology-Hemostaseology

3.3.8. Giroctocogene fitelparvovec - Orphan - EMEA-002724-PIP01-19-M02

Pfizer Europe MA EEIG; Treatment of haemophilia A

Day 30 discussion

Haematology-Hemostaseology

3.3.9. BNT162b2 / Tozinameran - EMEA-002861-PIP02-20-M03

BioNTech Manufacturing GmbH; Prevention of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.3.10. MK-1654 fully human IgG1 RB-1 YTE anti-RSV F monoclonal antibody - EMEA-002755-PIP01-19-M01

Merck Sharp & Dohme (Europe), Inc.; Prevention of lower respiratory tract infection caused by respiratory syncytial virus

Day 30 discussion

Infectious Diseases

3.3.11. Fenfluramine hydrochloride - Orphan - EMEA-001990-PIP01-16-M04

Zogenix International Ltd; Dravet syndrome

Day 30 discussion

Neurology

3.3.12. Risdiplam - Orphan - EMEA-002070-PIP01-16-M06

Roche Registration GmbH; Treatment of spinal muscular atrophy

Day 30 discussion

Neurology

3.3.13. Avelumab - EMEA-001849-PIP02-15-M04

Merck Healthcare KGaA; Treatment of malignant neoplasms of the central nervous system

Day 30 discussion

Oncology

3.3.14. Eribulin - EMEA-001261-PIP01-11-M07

Eisai GmbH; Soft tissue sarcoma

Day 30 discussion

Oncology

3.3.15. Lisocabtagene maraleucel - Orphan - EMEA-001995-PIP01-16-M03

Bristol-Myers Squibb Pharma EEIG; Treatment of B-lymphoblastic leukaemia/lymphoma / Treatment of mature B-cell neoplasms

Day 30 discussion

Oncology

3.3.16. Pembrolizumab - EMEA-001474-PIP02-16-M02

Merck Sharp & Dohme (Europe), Inc.; Treatment of Hodgkin lymphoma

Day 30 discussion

Oncology

3.3.17. Alpelisib - Orphan - EMEA-002016-PIP03-19-M01

Novartis Europharm Limited; Treatment of PIK3CA related overgrowth spectrum

Day 30 discussion

Other

3.3.18. Human thrombin (component 2) / Human fibrinogen (component 1) - EMEA-001598-PIP01-13-M04

Instituto Grifols, S.A.; Treatment of haemorrhage resulting from a surgical procedure

Day 30 discussion

Other

3.3.19. Palovarotene - Orphan - EMEA-001662-PIP01-14-M05

Ipsen Pharma; Treatment of fibrodysplasia ossificans progressiva

Day 30 discussion

Other

3.3.20. Synthetic double-stranded siRNA oligonucleotide directed against lactate dehydrogenase A mRNA and containing four modified nucleosides which form a ligand cluster of four N-acetylgalactosamine residues (DCR-PHXC, nedosiran) - Orphan - EMEA-002493-PIP01-18-M03

Dicerna Ireland Limited; Primary hyperoxaluria

Day 30 discussion

Uro-nephrology

4. Nominations

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 19 October 2021 for Nomination of Rapporteur and Peer reviewer

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

5.1. New Scientific Advice

No item

5.2. Final Scientific Advice (Reports and Scientific Advice letters)

No item

6. Discussion on the applicability of class waivers

6.1. Discussions on the applicability of class waiver for products

6.1.1. Paltusotine - EMEA-11-2021

Crinetics Pharmaceuticals, Inc.; The classes of androgen receptor modulator, of oestrogen receptor modulator, of growth and sex hormone as well as their releasing or inhibiting factors, and of sex hormone-metabolism modulator medicinal products for treatment of neuroendocrine malignant neoplasms / Treatment of carcinoid syndrome in patients with neuroendocrine malignant neoplasms.

Summary of Committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015

to the planned therapeutic indication was confirmed.

Other potential paediatric interests of this medicine suggested by PDCO: None identified at this stage.

6.1.2. Human plasma Kallikrein inhibitor for intravitreal injection (THR-149) - EMEA-13-2021

Oxurion NV; All classes of medicinal products for treatment of age-related macular degeneration and diabetic macular oedema / Treatment of diabetic macular oedema

Summary of Committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015

to the planned therapeutic indication was confirmed.

Other potential paediatric interests of this medicine suggested by PDCO: None identified at this stage.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

No item

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. PDCO membership

No item

9.1.2. Vote by proxy

No item

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of Committee discussion:

The PDCO members were informed about the list of procedures with paediatric indications, starting in September 2021 to be evaluated by the CHMP.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Karen van Malderen

Summary of Committee discussion:

The chair of the Non-clinical Working Group (NcWG) identified the products which will require NcWG evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of Committee discussion:

The Chair of the Formulation Working Group (FWG) identified the products which will require FWG evaluation and discussion.

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

Summary of Committee discussion:

The co-chair of Enpr-EMA updated the committee on the activities of Enpr-EMA during the past year, and provided a summary of the annual meeting of Enpr-EMA's coordinating group and networks, which took place on 28 September 2021.

9.5. Cooperation with International Regulators

No item

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

No item

9.7. PDCO Work Plan 2022

PDCO Chair: Koenraad Norga

Summary of Committee discussion:

The draft work plan for 2022 was presented to the committee.

9.8. Planning and reporting

No item

10. Any other business

10.1. COVID-19 update

Summary of Committee discussion:

The PDCO was updated on COVID vaccines, and in particular on the available data in paediatric population.

10.2. Update on resamirigene bilparvovec - EMEA-002571-PIP01-19

10.3. Presentation of the results and conclusions from the extrapolation project

Summary of Committee discussion:

The committee was informed that this topic will be postponed to the December plenary.

10.4. Registry-based studies guideline – update

Summary of Committee discussion:

The PDCO noted the finalisation of the Registry-based studies guideline and its adoption by CHMP in September 2021. The publication of the document is planned by end of October 2021.

Post meeting note: the guideline was published on 26 October 2021.

10.5. EMA Business Pipeline activity and Horizon scanning

Q3/2021 Update of the Business Pipeline report for the human scientific committees

Summary of Committee discussion:

The business pipeline report for Q3/2021 was provided for information.

10.6. Art 45 of the Paediatric Regulation (EC) 1901/2006 – worksharing project update

PDCO member: Siri Wang

Summary of Committee discussion:

Siri Wang presented (as chair of the Paediatric Regulation Working Party) the current status of the Art 45 project. A lot has been achieved, but the remaining workload is nevertheless significant. The work is resource intensive, much of the data is quite old, and the benefit/need/risk/cost is unclear. Some clear criteria to deprioritise/delete APIs and studies are being proposed, based on a risk-based approach, and PDCO was invited for input. PDCO reflected both concern regarding risk of losing potentially valuable data, but at the same time the need for pragmatism was also clearly acknowledged. Clinical input (on priorities/unmet need) might be offered by PDCO subgroups within some therapeutic areas, and proposals to liaise with Enpr EMA project was flagged. A small group of members volunteered to join an ad hoc TC on this topic. The issue will be further discussed within the Paediatric Regulation Working Party and with CMDh, and with representatives from the EC.

10.7.

10.8.

11. Breakout sessions

11.1. Neonatology

Summary of Committee discussion:

Discussion on approaches for clinical trials for treatment of neonatal seizures and the role of RWD/RWE in neonatology.

11.2. Paediatric oncology

Summary of Committee discussion:

The breakout session was cancelled as no topic of relevance was identified.

11.3. Vaccines

Summary of Committee discussion:

The PDCO discussed the events of myocarditis with mRNA vaccines vis-à-vis the currently ongoing COVID vaccine PIPs. Members from other Committee also participated to the session.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 12-15 October 2021 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Koenraad Norga	Chair	Belgium	When chairing the meeting: To be replaced for discussions, final deliberations and voting When not chairing the meeting: No participation in final deliberations and voting	2.1.23. Depemokimab - EMEA-003051-PIP02-21 2.1.24. Depemokimab - EMEA-003051-PIP03-21 2.3.21. Sotrovimab - EMEA-002899-PIP01-20-M01 3.1.32. Bepirovirsen - EMEA-003082-PIP01-21 2.7.8 Daprodustat - EMEA-C1-001452-PIP01-13-M03
Karl-Heinz Huemer	Member	Austria	No interests declared	
Marleen Renard	Member	Belgium	No participation in discussions, final deliberations and voting on: No participation in final deliberations and voting on:	2.3.31. Ruxolitinib phosphate - EMEA-000901-PIP04-17-M02 3.3.12. Avelumab - EMEA-001849-PIP02-15-M04
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable for the meeting	
Tereza Bazantova	Alternate	Czechia	No interests declared	
Nanna Borup Johansen	Member	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Pauliina Lehtolainen-Dalkilic	Member	Finland	No interests declared	
Anne Paavola	Alternate	Finland	No interests declared	
Sylvie Benchetrit	Member	France	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member (Vice-Chair)	Germany	No interests declared	
Yuansheng Sun	Alternate	Germany	No interests declared	
Eleni	Member	Greece	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Katsomiti				
Anastasia Mountaki	Alternate	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable for the meeting	
Silvijus Abramavicius	Alternate	Lithuania	No restrictions applicable for the meeting	
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No interests declared	
Herbert Lenicker	Alternate	Malta	No interests declared	
Roderick Houwen	Member	Netherlands	No restrictions applicable for the meeting	
Maaike van Dartel	Alternate	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Anette Solli Karlsen	Alternate	Norway	No interests declared	
Marek Migdal	Member	Poland	No restrictions applicable for the meeting	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Peter Szitanyi	Alternate	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	
Eva Agurell	Member	Sweden	No interests declared	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Fernando Cabanas	Member	Healthcare Professionals'	No restrictions applicable for the	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
		Representative	meeting	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable for the meeting	
Catherine Cornu	Alternate	Healthcare Professionals' Representative	No participation in final deliberations and voting on	2.3.37. Lumasiran sodium - Orphan - EMEA-002079-PIP01-16-M02
Jaroslav Sterba	Member	Patients' Organisation Representative	No interests declared	
Tomasz Grybek	Alternate	Patients' Organisation Representative	No interests declared	
Michal Odermarsky	Alternate	Patients' Organisation Representative	No restrictions applicable for the meeting	
María Estela Moreno Martín	Expert - via telephone*	Spain	No interests declared	
Lutz Wiesner	Expert - via telephone*	Germany	No interests declared	
Menno van der Elst	Expert - via telephone*	Netherlands	No interests declared	
Charlotta Bergquist	Expert - via telephone*	Sweden	No interests declared	
Filip Josephson	Expert - via telephone*	Sweden	No interests declared	
Meeting run with support from relevant EMA staff				
* Experts were evaluated against the agenda topics or activities they participated in				

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/